Non-Small Cell Lung Cancer
Conditions
Brief summary
This multicenter, single-arm study will evaluate the efficacy and safety of atezolizumab (MPDL3280A) in participants with PD-L1-positive locally advanced or metastatic NSCLC. Participants will receive an intravenous (IV) dose of 1200 milligrams (mg) atezolizumab (MPDL3280A) on Day 1 of 21-day cycles until disease progression. Eligible participants will be categorized in to three groups as follows: 1. Participants with no prior chemotherapy for advanced disease; 2. Participants who progress during or following a prior-platinum based chemotherapy regimen for advanced disease (2L+participants); 3. Participants who are 2L+ and previously treated for brain metastases.
Interventions
Atezolizumab 1200 mg IV on Day 1 of each 21-day cycle until disease progression.
Sponsors
Genentech, Inc.
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Stage IIIB (not eligible for definitive chemoradiotherapy), Stage IV, or recurrent NSCLC * PDL1-positive status as determined by an immunohistochemistry assay performed by a central laboratory. A positive result in chemotherapy, chemoradiation of the tumor sample biopsy will satisfy the eligibility criterion * Eastern Cooperative Oncology group Performance Status of 0 or 1 * Life expectancy greater than or equal to 12 weeks * Measurable disease, as defined by Response Evaluation Criteria in Solid Tumors Version 1.1 * Adequate hematologic and end organ function
Exclusion criteria
* Any approved anti-cancer therapy, including chemotherapy, or hormonal therapy within 3 weeks prior to initiation of study treatment; the following exceptions are allowed. Hormone-replacement therapy or oral contraceptives, and tyrosine kinase inhibitors approved for treatment of NSCLC discontinued greater than 7 days prior to Cycle 1 Day 1 * Treatment with any other investigational agent or participation in another clinical trial with therapeutic intent within 28 days prior to enrollment * Known central nervous system disease, including treated brain metastases in the following participants: 1. who will not receive prior chemotherapy for advanced disease 2. who progress during or following a prior-platinum based chemotherapy regimen for advanced disease (referred as 2L+ participants) * Participants with a history of treated asymptomatic brain metastases are allowed in the 2L+ participants and previously treated for brain metastases. * Leptomeningeal disease * Uncontrolled tumor-related pain * Uncontrolled hypercalcemia
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Participants With Objective Response According to Modified Response Evaluation Criteria in Solid Tumors (RECIST) | Baseline, and Day 1 of Cycle 1 (21-day cycle), then every 6 weeks for the first 12 months and then every 9 weeks thereafter until disease progression (up to 20 months) | Objective response was defined as a complete response (CR) or partial response (PR), as determined by investigator according to modified RECIST criteria. Modified RECIST was derived from RECIST v1.1 conventions and immune related response criteria. CR was defined as disappearance of all tumor lesions (target lesion \[TL\] and non-target lesion \[non-TL\]) and no new measurable or unmeasurable lesions, all lymph node short axes must be less than 10 millimeters (mm), and PR was defined as at least 30 percent (%) decrease in sum of diameter of TLs and all new measurable lesions since baseline in absence of CR, and both confirmed by consecutive assessment greater than or equal to 4 weeks from date first documented. Participants not meeting these criteria, including participants without at least one post-baseline response assessment were considered as non-responders. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Duration of Objective Response According to RECIST v1.1 | Baseline, and Day 1 of Cycle 1 (21-day cycle), then every 6 weeks for the first 12 months and then every 9 weeks thereafter until disease progression (up to 20 months) | Duration of objective response was defined as time from initial occurrence of documented CR or PR until documented disease progression (using RECIST v1.1 as determined by investigator) or death, whichever occurred first. For TLs, CR was defined as disappearance of all TLs. Any pathological lymph nodes, whether target or non-target, must had reduction in short axis to less than 10 mm. PR was defined as at least a 30% decrease in sum of diameter of TLs, taking as reference baseline sum of diameters, in absence of CR. Progressive disease was at least a 20% increase in sum of diameters of TLs, taking as reference smallest sum on study (nadir). For non-TLs, CR was defined as disappearance of all non-TLs and if applicable, normalization of tumor marker level. Progressive disease was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs. Participants were censored at the date of last tumor assessment. |
| Percentage of Participants With 6-Month Duration of Objective Response | Month 6 | Duration of objective response at 6 months was defined as time from initial occurrence of documented CR or PR until Month 6. For TLs, CR was defined as disappearance of all TLs. Any pathological lymph nodes, whether target or non-target, must have reduction in short axis to less than 10 mm. PR was defined as at least a 30% decrease in sum of diameter of TLs, taking as reference baseline sum of diameters, in absence of CR. For non-TLs, CR was defined as disappearance of all non-TLs and if applicable, normalization of tumor marker level. Participants were censored at the date of last tumor assessment. |
| Percentage of Participants With Disease Progression or Death According to RECIST v1.1 | Baseline to the first occurrence of progression or death, whichever occurs earlier (up to 20 months) | For TLs, progressive disease was defined as at least a 20% increase in the sum of diameters of TLs, taking as reference the smallest sum on study (nadir). For non-TLs, progressive disease was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs. |
| Progression-Free Survival (PFS) According to RECIST v1.1 | Baseline to the first occurrence of progression or death, whichever occurs earlier (up to 20 months) | PFS was defined as time from randomization to first occurrence of documented disease progression (based on RECIST v1.1 criteria) or death due to any cause within 30 days of the last treatment, whichever occurs earlier as determined by investigator. For TLs, progressive disease was defined as at least a 20% increase in the sum of diameter of TLs, taking as reference the smallest sum on study (nadir). For non-TLs, progressive disease was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs. In event of no disease progression or documented death, PFS was censored at date of last evaluable tumor assessment. Participants with no post-baseline tumor assessments were censored at the time of first dose plus 1 day. |
| Percentage of Participants With PFS at Month 6, Month 12 and Month 30 According to RECIST v1.1 | Months 6, 12 and 30 | Percentage of participants who were progression free at Month 6 and 12 (based on RECIST v1.1) was reported. For TLs, progressive disease was defined as at least a 20% increase in the sum of diameter of TLs, taking as reference the smallest sum on study (nadir). For non-TLs, progressive disease was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs. |
| Percentage of Participants With Disease Progression or Death According to Modified RECIST | Baseline to the first occurrence of progression or death, whichever occurs earlier (up to 20 months) | For TLs, progressive disease was defined as at least a 20% increase in the sum of diameters of TLs and new measurable lesions, taking as reference the smallest sum recorded since treatment started. |
| Percentage of Participants With Objective Response According to RECIST Version 1.1 (v1.1) | Baseline, and Day 1 of Cycle 1 (21-day cycle), then every 6 weeks for the first 12 months and then every 9 weeks thereafter until disease progression (up to 20 months) | Objective response was defined as a CR or PR, as determined by the investigator according to RECIST v1.1. For TLs, CR was defined as disappearance of all TLs. Any pathological lymph nodes, whether target or non-target, must had reduction in short axis to less than 10 mm. PR was defined as at least a 30% decrease in the sum of diameter of TLs, taking as reference the baseline sum of diameters, in absence of CR. For non-TLs, CR was defined as disappearance of all non-TLs and if applicable, normalization of tumor marker level. Participants not meeting these criteria, including participants without at least 1 post-baseline response assessment were considered as non-responders. |
| Percentage of Participants With PFS at Month 6, Month 12 and Month 30 According to Modified RECIST | Months 6, 12 and 30 | Percentage of participants who were progression free at Months 6 and 12 (according to modified RECIST). For TLs, progressive disease was defined as at least a 20% increase in the sum of diameters of TLs and new measurable lesions, taking as reference the smallest sum recorded since treatment started. |
| Percentage of Participants With Death | Baseline till death or up to 20 months, whichever occurred first | Participants were followed for survival throughout the study. |
| Overall Survival (OS) | Baseline till death or up to 20 months, whichever occurred first | OS was defined as the time from first dose of the study drug to the time of death from any cause of the study. Participants who were still alive at the time of analysis were censored at the time of their last study assessment (for active participants) or at the last date known alive (for participants in follow-up). If no post-baseline data were available, OS was censored at the date of first treatment plus 1 day. |
| Maximum Plasma Concentration (Cmax) for Atezolizumab | Pre-dose (0 hour) and 30 minutes after infusion on Day 1 of Cycle 1 | — |
| Minimum Plasma Concentration (Cmin) for Atezolizumab | Pre-dose (0 hour) on Day 1 of Cycles 2, 3, 4, 8, and 16 | — |
| PFS According to Modified RECIST | Baseline to the first occurrence of progression or death, whichever occurs earlier (up to 20 months) | PFS according to modified RECIST was defined as time from first dose of atezolizumab to first occurrence of documented disease progression or death due to any cause, as determined by investigator for participants who discontinued at first documented radiographic progression. For participants who continued beyond first documented progression and had follow-up tumor assessment or death, PFS was defined as time from first dose of atezolizumab to subsequent radiographic progression or death. For TLs, progressive disease was defined as at least a 20% increase in the sum of diameters of TLs and new measurable lesions, taking as reference the smallest sum recorded since treatment started. In event of no disease progression or documented death, PFS was censored at date of last evaluable tumor assessment. |
Countries
Belgium, France, Netherlands, United Kingdom, United States
Participant flow
Pre-assignment details
Overall 201 participants were screened for clinical eligibility, out of which 63 participants were screen failures, and hence 138 participants were enrolled, and 137 participants received treatment.
Participants by arm
| Arm | Count |
|---|---|
| Atezolizumab (MPDL3280) : 1L Participants Participants with no prior chemotherapy for advanced NSCLC disease received atezolizumab IV as a fixed dose of 1200-mg on Day 1 of each 21-day cycle until disease progression. | 31 |
| Atezolizumab (MPDL3280) : 2L+ Participants Participants who had progressed during or following a prior platinum-based chemotherapy regimen without restriction to maximum number of prior therapies received atezolizumab IV as a fixed dose of 1200-mg on Day 1 of each 21-day cycle until no longer deemed to be experiencing clinical benefit as assessed by the investigator. | 93 |
| Atezolizumab (MPDL3280) : 2L+ Brain Metastases Participants Participants with previously treated brain metastases and who had progressed during or following a prior platinum-based chemotherapy regimen without restriction to the maximum number of prior therapies, received atezolizumab IV as a fixed dose of 1200-mg on Day 1 of each 21-day cycle until no longer deemed to be experiencing clinical benefit as assessed by the investigator. | 13 |
| Total | 137 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 |
|---|---|---|---|---|
| Survival Follow-up | Death | 21 | 62 | 9 |
| Survival Follow-up | Lost to Follow-up | 0 | 2 | 2 |
| Survival Follow-up | Other | 3 | 1 | 1 |
| Survival Follow-up | Study Terminated by Sponsor | 2 | 8 | 0 |
| Survival Follow-up | Withdrawal by Subject | 2 | 7 | 0 |
| Treatment Phase | Adverse Event | 3 | 4 | 0 |
| Treatment Phase | Death | 2 | 9 | 1 |
| Treatment Phase | Non-compliance | 0 | 2 | 0 |
| Treatment Phase | Other | 1 | 5 | 1 |
| Treatment Phase | Physician Decision | 1 | 2 | 0 |
| Treatment Phase | Progressive Disease | 21 | 63 | 9 |
| Treatment Phase | Study Terminated by Sponsor | 1 | 4 | 0 |
| Treatment Phase | Withdrawal by Subject | 2 | 4 | 2 |
Baseline characteristics
| Characteristic | Atezolizumab (MPDL3280) : 1L Participants | Atezolizumab (MPDL3280) : 2L+ Participants | Atezolizumab (MPDL3280) : 2L+ Brain Metastases Participants | Total |
|---|---|---|---|---|
| Age, Continuous | 68 years STANDARD_DEVIATION 10.8 | 65.2 years STANDARD_DEVIATION 9.3 | 63.8 years STANDARD_DEVIATION 7.7 | 65.7 years STANDARD_DEVIATION 9.6 |
| Sex: Female, Male Female | 17 Participants | 34 Participants | 7 Participants | 58 Participants |
| Sex: Female, Male Male | 14 Participants | 59 Participants | 6 Participants | 79 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — | — / — |
| other Total, other adverse events | 31 / 31 | 88 / 93 | 13 / 13 |
| serious Total, serious adverse events | 17 / 31 | 46 / 93 | 6 / 13 |
Outcome results
Primary
Percentage of Participants With Objective Response According to Modified Response Evaluation Criteria in Solid Tumors (RECIST)
Objective response was defined as a complete response (CR) or partial response (PR), as determined by investigator according to modified RECIST criteria. Modified RECIST was derived from RECIST v1.1 conventions and immune related response criteria. CR was defined as disappearance of all tumor lesions (target lesion \[TL\] and non-target lesion \[non-TL\]) and no new measurable or unmeasurable lesions, all lymph node short axes must be less than 10 millimeters (mm), and PR was defined as at least 30 percent (%) decrease in sum of diameter of TLs and all new measurable lesions since baseline in absence of CR, and both confirmed by consecutive assessment greater than or equal to 4 weeks from date first documented. Participants not meeting these criteria, including participants without at least one post-baseline response assessment were considered as non-responders.
Time frame: Baseline, and Day 1 of Cycle 1 (21-day cycle), then every 6 weeks for the first 12 months and then every 9 weeks thereafter until disease progression (up to 20 months)
Population: Efficacy-evaluable population; all treated participants who received at least 1 dose of atezolizumab during study.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Atezolizumab (MPDL3280) : 1L Participants | Percentage of Participants With Objective Response According to Modified Response Evaluation Criteria in Solid Tumors (RECIST) | 32 percentage of participants |
| Atezolizumab (MPDL3280) : 2L+ Participants | Percentage of Participants With Objective Response According to Modified Response Evaluation Criteria in Solid Tumors (RECIST) | 21 percentage of participants |
| Atezolizumab (MPDL3280) : 2L+ Brain Metastases Participants | Percentage of Participants With Objective Response According to Modified Response Evaluation Criteria in Solid Tumors (RECIST) | 23 percentage of participants |
Secondary
Duration of Objective Response According to RECIST v1.1
Duration of objective response was defined as time from initial occurrence of documented CR or PR until documented disease progression (using RECIST v1.1 as determined by investigator) or death, whichever occurred first. For TLs, CR was defined as disappearance of all TLs. Any pathological lymph nodes, whether target or non-target, must had reduction in short axis to less than 10 mm. PR was defined as at least a 30% decrease in sum of diameter of TLs, taking as reference baseline sum of diameters, in absence of CR. Progressive disease was at least a 20% increase in sum of diameters of TLs, taking as reference smallest sum on study (nadir). For non-TLs, CR was defined as disappearance of all non-TLs and if applicable, normalization of tumor marker level. Progressive disease was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs. Participants were censored at the date of last tumor assessment.
Time frame: Baseline, and Day 1 of Cycle 1 (21-day cycle), then every 6 weeks for the first 12 months and then every 9 weeks thereafter until disease progression (up to 20 months)
Population: Efficacy-evaluable population with a confirmed objective response.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Atezolizumab (MPDL3280) : 1L Participants | Duration of Objective Response According to RECIST v1.1 | 9.2 months |
| Atezolizumab (MPDL3280) : 2L+ Participants | Duration of Objective Response According to RECIST v1.1 | 17.0 months |
| Atezolizumab (MPDL3280) : 2L+ Brain Metastases Participants | Duration of Objective Response According to RECIST v1.1 | NA months |
Secondary
Maximum Plasma Concentration (Cmax) for Atezolizumab
Time frame: Pre-dose (0 hour) and 30 minutes after infusion on Day 1 of Cycle 1
Population: Pharmacokinetic- evaluable population: All treated participants with pharmacokinetic data at specified time points. Here, Number of participants analyzed = number of participants with available data for this outcome. Per planned analysis, pharmacokinetic data were not analyzed separately for each cohort.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Atezolizumab (MPDL3280) : 1L Participants | Maximum Plasma Concentration (Cmax) for Atezolizumab | 405 micrograms per milliliter (mcg/mL) | Geometric Coefficient of Variation 31.7 |
Secondary
Minimum Plasma Concentration (Cmin) for Atezolizumab
Time frame: Pre-dose (0 hour) on Day 1 of Cycles 2, 3, 4, 8, and 16
Population: Pharmacokinetic- evaluable population. Here, Number of participants analyzed = number of participants with available data for this outcome, and n= number of participants with available data at the specified time point. Per planned analysis, pharmacokinetic data were not analyzed separately for each cohort.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| Atezolizumab (MPDL3280) : 1L Participants | Minimum Plasma Concentration (Cmin) for Atezolizumab | Pre-dose Cycle 2 (Day 1) (n= 125) | 68.8 mcg/mL | Geometric Coefficient of Variation 55.3 |
| Atezolizumab (MPDL3280) : 1L Participants | Minimum Plasma Concentration (Cmin) for Atezolizumab | Pre-dose Cycle 3 (Day 1) (n= 100) | 90.6 mcg/mL | Geometric Coefficient of Variation 136.6 |
| Atezolizumab (MPDL3280) : 1L Participants | Minimum Plasma Concentration (Cmin) for Atezolizumab | Pre-dose Cycle 4 (Day 1) (n= 92) | 123 mcg/mL | Geometric Coefficient of Variation 136.9 |
| Atezolizumab (MPDL3280) : 1L Participants | Minimum Plasma Concentration (Cmin) for Atezolizumab | Pre-dose Cycle 8 (Day 1) (n= 51) | 206 mcg/mL | Geometric Coefficient of Variation 45.9 |
| Atezolizumab (MPDL3280) : 1L Participants | Minimum Plasma Concentration (Cmin) for Atezolizumab | Pre-dose Cycle 16 (Day 1) (n= 1) | 135 mcg/mL | — |
Secondary
Overall Survival (OS)
OS was defined as the time from first dose of the study drug to the time of death from any cause of the study. Participants who were still alive at the time of analysis were censored at the time of their last study assessment (for active participants) or at the last date known alive (for participants in follow-up). If no post-baseline data were available, OS was censored at the date of first treatment plus 1 day.
Time frame: Baseline till death or up to 20 months, whichever occurred first
Population: Efficacy-evaluable population.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Atezolizumab (MPDL3280) : 1L Participants | Overall Survival (OS) | 14.4 months |
| Atezolizumab (MPDL3280) : 2L+ Participants | Overall Survival (OS) | 9.3 months |
| Atezolizumab (MPDL3280) : 2L+ Brain Metastases Participants | Overall Survival (OS) | 6.8 months |
Secondary
Percentage of Participants With 6-Month Duration of Objective Response
Duration of objective response at 6 months was defined as time from initial occurrence of documented CR or PR until Month 6. For TLs, CR was defined as disappearance of all TLs. Any pathological lymph nodes, whether target or non-target, must have reduction in short axis to less than 10 mm. PR was defined as at least a 30% decrease in sum of diameter of TLs, taking as reference baseline sum of diameters, in absence of CR. For non-TLs, CR was defined as disappearance of all non-TLs and if applicable, normalization of tumor marker level. Participants were censored at the date of last tumor assessment.
Time frame: Month 6
Population: Efficacy-evaluable population with a confirmed objective response.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Atezolizumab (MPDL3280) : 1L Participants | Percentage of Participants With 6-Month Duration of Objective Response | 75.0 percentage of participants |
| Atezolizumab (MPDL3280) : 2L+ Participants | Percentage of Participants With 6-Month Duration of Objective Response | 91.7 percentage of participants |
| Atezolizumab (MPDL3280) : 2L+ Brain Metastases Participants | Percentage of Participants With 6-Month Duration of Objective Response | 66.7 percentage of participants |
Secondary
Percentage of Participants With Death
Participants were followed for survival throughout the study.
Time frame: Baseline till death or up to 20 months, whichever occurred first
Population: Efficacy-evaluable population.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Atezolizumab (MPDL3280) : 1L Participants | Percentage of Participants With Death | 74.2 percentage of participants |
| Atezolizumab (MPDL3280) : 2L+ Participants | Percentage of Participants With Death | 76.3 percentage of participants |
| Atezolizumab (MPDL3280) : 2L+ Brain Metastases Participants | Percentage of Participants With Death | 76.9 percentage of participants |
Secondary
Percentage of Participants With Disease Progression or Death According to Modified RECIST
For TLs, progressive disease was defined as at least a 20% increase in the sum of diameters of TLs and new measurable lesions, taking as reference the smallest sum recorded since treatment started.
Time frame: Baseline to the first occurrence of progression or death, whichever occurs earlier (up to 20 months)
Population: Efficacy-evaluable population.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Atezolizumab (MPDL3280) : 1L Participants | Percentage of Participants With Disease Progression or Death According to Modified RECIST | 58.1 percentage of participants |
| Atezolizumab (MPDL3280) : 2L+ Participants | Percentage of Participants With Disease Progression or Death According to Modified RECIST | 66.7 percentage of participants |
| Atezolizumab (MPDL3280) : 2L+ Brain Metastases Participants | Percentage of Participants With Disease Progression or Death According to Modified RECIST | 69.2 percentage of participants |
Secondary
Percentage of Participants With Disease Progression or Death According to RECIST v1.1
For TLs, progressive disease was defined as at least a 20% increase in the sum of diameters of TLs, taking as reference the smallest sum on study (nadir). For non-TLs, progressive disease was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs.
Time frame: Baseline to the first occurrence of progression or death, whichever occurs earlier (up to 20 months)
Population: Efficacy-evaluable population.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Atezolizumab (MPDL3280) : 1L Participants | Percentage of Participants With Disease Progression or Death According to RECIST v1.1 | 67.7 percentage of participants |
| Atezolizumab (MPDL3280) : 2L+ Participants | Percentage of Participants With Disease Progression or Death According to RECIST v1.1 | 74.2 percentage of participants |
| Atezolizumab (MPDL3280) : 2L+ Brain Metastases Participants | Percentage of Participants With Disease Progression or Death According to RECIST v1.1 | 84.6 percentage of participants |
Secondary
Percentage of Participants With Objective Response According to RECIST Version 1.1 (v1.1)
Objective response was defined as a CR or PR, as determined by the investigator according to RECIST v1.1. For TLs, CR was defined as disappearance of all TLs. Any pathological lymph nodes, whether target or non-target, must had reduction in short axis to less than 10 mm. PR was defined as at least a 30% decrease in the sum of diameter of TLs, taking as reference the baseline sum of diameters, in absence of CR. For non-TLs, CR was defined as disappearance of all non-TLs and if applicable, normalization of tumor marker level. Participants not meeting these criteria, including participants without at least 1 post-baseline response assessment were considered as non-responders.
Time frame: Baseline, and Day 1 of Cycle 1 (21-day cycle), then every 6 weeks for the first 12 months and then every 9 weeks thereafter until disease progression (up to 20 months)
Population: Efficacy-evaluable population.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Atezolizumab (MPDL3280) : 1L Participants | Percentage of Participants With Objective Response According to RECIST Version 1.1 (v1.1) | 29 percentage of participants |
| Atezolizumab (MPDL3280) : 2L+ Participants | Percentage of Participants With Objective Response According to RECIST Version 1.1 (v1.1) | 19 percentage of participants |
| Atezolizumab (MPDL3280) : 2L+ Brain Metastases Participants | Percentage of Participants With Objective Response According to RECIST Version 1.1 (v1.1) | 23 percentage of participants |
Secondary
Percentage of Participants With PFS at Month 6, Month 12 and Month 30 According to Modified RECIST
Percentage of participants who were progression free at Months 6 and 12 (according to modified RECIST). For TLs, progressive disease was defined as at least a 20% increase in the sum of diameters of TLs and new measurable lesions, taking as reference the smallest sum recorded since treatment started.
Time frame: Months 6, 12 and 30
Population: Efficacy-evaluable population.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Atezolizumab (MPDL3280) : 1L Participants | Percentage of Participants With PFS at Month 6, Month 12 and Month 30 According to Modified RECIST | Month 12 | 31 percentage of participants |
| Atezolizumab (MPDL3280) : 1L Participants | Percentage of Participants With PFS at Month 6, Month 12 and Month 30 According to Modified RECIST | Month 6 | 43.12 percentage of participants |
| Atezolizumab (MPDL3280) : 1L Participants | Percentage of Participants With PFS at Month 6, Month 12 and Month 30 According to Modified RECIST | Month 30 | 12 percentage of participants |
| Atezolizumab (MPDL3280) : 2L+ Participants | Percentage of Participants With PFS at Month 6, Month 12 and Month 30 According to Modified RECIST | Month 12 | 29 percentage of participants |
| Atezolizumab (MPDL3280) : 2L+ Participants | Percentage of Participants With PFS at Month 6, Month 12 and Month 30 According to Modified RECIST | Month 6 | 39.10 percentage of participants |
| Atezolizumab (MPDL3280) : 2L+ Participants | Percentage of Participants With PFS at Month 6, Month 12 and Month 30 According to Modified RECIST | Month 30 | 10 percentage of participants |
| Atezolizumab (MPDL3280) : 2L+ Brain Metastases Participants | Percentage of Participants With PFS at Month 6, Month 12 and Month 30 According to Modified RECIST | Month 6 | 44.87 percentage of participants |
| Atezolizumab (MPDL3280) : 2L+ Brain Metastases Participants | Percentage of Participants With PFS at Month 6, Month 12 and Month 30 According to Modified RECIST | Month 30 | NA percentage of participants |
| Atezolizumab (MPDL3280) : 2L+ Brain Metastases Participants | Percentage of Participants With PFS at Month 6, Month 12 and Month 30 According to Modified RECIST | Month 12 | 24 percentage of participants |
Secondary
Percentage of Participants With PFS at Month 6, Month 12 and Month 30 According to RECIST v1.1
Percentage of participants who were progression free at Month 6 and 12 (based on RECIST v1.1) was reported. For TLs, progressive disease was defined as at least a 20% increase in the sum of diameter of TLs, taking as reference the smallest sum on study (nadir). For non-TLs, progressive disease was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs.
Time frame: Months 6, 12 and 30
Population: Efficacy-evaluable population.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Atezolizumab (MPDL3280) : 1L Participants | Percentage of Participants With PFS at Month 6, Month 12 and Month 30 According to RECIST v1.1 | Month 12 | 20 percentage of participants |
| Atezolizumab (MPDL3280) : 1L Participants | Percentage of Participants With PFS at Month 6, Month 12 and Month 30 According to RECIST v1.1 | Month 6 | 33.50 percentage of participants |
| Atezolizumab (MPDL3280) : 1L Participants | Percentage of Participants With PFS at Month 6, Month 12 and Month 30 According to RECIST v1.1 | Month 30 | 13 percentage of participants |
| Atezolizumab (MPDL3280) : 2L+ Participants | Percentage of Participants With PFS at Month 6, Month 12 and Month 30 According to RECIST v1.1 | Month 12 | 23 percentage of participants |
| Atezolizumab (MPDL3280) : 2L+ Participants | Percentage of Participants With PFS at Month 6, Month 12 and Month 30 According to RECIST v1.1 | Month 6 | 32.29 percentage of participants |
| Atezolizumab (MPDL3280) : 2L+ Participants | Percentage of Participants With PFS at Month 6, Month 12 and Month 30 According to RECIST v1.1 | Month 30 | 10 percentage of participants |
| Atezolizumab (MPDL3280) : 2L+ Brain Metastases Participants | Percentage of Participants With PFS at Month 6, Month 12 and Month 30 According to RECIST v1.1 | Month 6 | 15.38 percentage of participants |
| Atezolizumab (MPDL3280) : 2L+ Brain Metastases Participants | Percentage of Participants With PFS at Month 6, Month 12 and Month 30 According to RECIST v1.1 | Month 30 | NA percentage of participants |
| Atezolizumab (MPDL3280) : 2L+ Brain Metastases Participants | Percentage of Participants With PFS at Month 6, Month 12 and Month 30 According to RECIST v1.1 | Month 12 | NA percentage of participants |
Secondary
PFS According to Modified RECIST
PFS according to modified RECIST was defined as time from first dose of atezolizumab to first occurrence of documented disease progression or death due to any cause, as determined by investigator for participants who discontinued at first documented radiographic progression. For participants who continued beyond first documented progression and had follow-up tumor assessment or death, PFS was defined as time from first dose of atezolizumab to subsequent radiographic progression or death. For TLs, progressive disease was defined as at least a 20% increase in the sum of diameters of TLs and new measurable lesions, taking as reference the smallest sum recorded since treatment started. In event of no disease progression or documented death, PFS was censored at date of last evaluable tumor assessment.
Time frame: Baseline to the first occurrence of progression or death, whichever occurs earlier (up to 20 months)
Population: Efficacy-evaluable population.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Atezolizumab (MPDL3280) : 1L Participants | PFS According to Modified RECIST | 5.5 months |
| Atezolizumab (MPDL3280) : 2L+ Participants | PFS According to Modified RECIST | 3.7 months |
| Atezolizumab (MPDL3280) : 2L+ Brain Metastases Participants | PFS According to Modified RECIST | 4.3 months |
Secondary
Progression-Free Survival (PFS) According to RECIST v1.1
PFS was defined as time from randomization to first occurrence of documented disease progression (based on RECIST v1.1 criteria) or death due to any cause within 30 days of the last treatment, whichever occurs earlier as determined by investigator. For TLs, progressive disease was defined as at least a 20% increase in the sum of diameter of TLs, taking as reference the smallest sum on study (nadir). For non-TLs, progressive disease was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs. In event of no disease progression or documented death, PFS was censored at date of last evaluable tumor assessment. Participants with no post-baseline tumor assessments were censored at the time of first dose plus 1 day.
Time frame: Baseline to the first occurrence of progression or death, whichever occurs earlier (up to 20 months)
Population: Efficacy-evaluable population.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Atezolizumab (MPDL3280) : 1L Participants | Progression-Free Survival (PFS) According to RECIST v1.1 | 4.5 months |
| Atezolizumab (MPDL3280) : 2L+ Participants | Progression-Free Survival (PFS) According to RECIST v1.1 | 2.7 months |
| Atezolizumab (MPDL3280) : 2L+ Brain Metastases Participants | Progression-Free Survival (PFS) According to RECIST v1.1 | 2.5 months |